[{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for 3-((4-(1-((1-(6-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)pyridin-3-yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)-5-((R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl)pyrazine-2-carboxamide
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
